We have an exciting PhD studentship on offer:
Machine learning approaches to improve the treatment of prostate cancer
RNA Biology Group<http://www.cruk.manchester.ac.uk/Research/CRUK-MI-Groups/RNA-Biology-Computational-Biology/Home> - Prostate Cancer UK (PCUK) funded 4 year PhD Studentship
Prostate Cancer is a highly heterogeneous disease with complex characteristics of progression. New therapies have produced some clinical successes, but a subset of patients progress to incurable disease and it is not yet possible to predict which patients will respond best to which treatments. There is an urgent need to develop better biomarkers with which to stratify patient populations and to personalise therapies in order improve clinical outcome.
This studentship, which is open to exceptional candidates from a computational background, will use techniques from machine learning to develop new models of prostate cancer gene expression. The successful applicant will have access to a large High Performance Computing (HPC) facility on site, and will join a highly interdisciplinary research programme that integrates computer science and machine learning, with basic- and clinical-science.
The project will focus on the role played by noncoding RNAs, a newly discovered set of genes that often regulate other processes within our cells. It will use computational techniques to study the changes in gene expression that accompany drug treatments, and then use these insights to develop novel biomarkers predictive of patient response.
No prior knowledge of cancer biology is required; applicants from artificial intelligence, mathematics, physics or other numerical disciplines are particularly encouraged to apply.
Full details on our website: cruk.manchester.ac.uk<http://cruk.manchester.ac.uk>
Crispin Miller | Group Leader RNA Biology Group | Computational Biology | CRUK Manchester Institute
CRUK Lung Cancer Centre of Excellence at Manchester and UCL | Movember Belfast-Manchester Centre of Excellence
This email is confidential and intended solely for the use of the person(s) ('the intended recipient') to whom it was addressed. Any views or opinions presented are solely those of the author and do not necessarily represent those of the Cancer Research UK Manchester Institute or the University of Manchester. It may contain information that is privileged & confidential within the meaning of applicable law. Accordingly any dissemination, distribution, copying, or other use of this message, or any of its contents, by any person other than the intended recipient may constitute a breach of civil or criminal law and is strictly prohibited. If you are NOT the intended recipient please contact the sender and dispose of this e-mail as soon as possible.
You may leave the list at any time by sending the command
to [log in to unmask], leaving the subject line blank.